Texas’s StatLab Medical products signs definitive agreement with Diapath

Texas’s StatLab Medical Products, a leading global developer and manufacturer of medical diagnostic supplies and equipment, announced that it has entered into an agreement to acquire Diapath S.p.A., a prominent Italian manufacturer of histology and cytology products and equipment. The integration of Diapath, with its innovative equipment offerings, manufacturing capabilities, and established customer base across Europe, Asia-Pacific, Middle East and Africa, and Latin America, positions StatLab to expand its market access, unlocking significant potential for growth and enhancing its global leadership.

Diapath’s equipment portfolio broadly includes tissue processors, stainers, embedding centers, and microtomes. The transaction is expected to close during the third quarter of 2024, subject to regulatory approvals.

“This combination is a pivotal milestone in our strategy to manufacture the full array of products supporting the entire anatomic pathology workflow,” said Sung-Dae Hong, CEO of StatLab. “Our partnership with Diapath will provide an opportunity to expand their equipment brand throughout global markets, including the U.S. The combination will also enhance StatLab’s European market access for slides, cassettes, and printers, driving our product innovation and manufacturing excellence to the next level.”